The difference between Lipofectamine and eGFP-VLPs did not reach statistical significance (ns), reflecting the variability observed in the Lipofectamine-treated replicates.
← all excerpts
Design and <i>in vitro</i> validation of Brome mosaic -virus-like particles for gene delivery and immunomodulation of melanoma.
1
—
—